We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of a microarray-based genotyping assay for the rapid detection of cytochrome P450 2C19 *2 and *3 polymorphisms from whole blood using nanoparticle probes.
- Authors
Buchan, Blake W.; Peterson, Jess F.; Cogbill, Christopher H.; Anderson, Dennis K.; Ledford, Joellen S.; White, Mary N.; Quigley, Neil B.; Jannetto, Paul J.; Ledeboer, Nathan A.
- Abstract
Numerous drugs such as clopidogrel have been developed to reduce coagulation or inhibit platelet function. The hepatic cytochrome P450 (CYP) pathway is involved in the conversion of clopidogrel to its active metabolite. A recent black-box warning was included in the clopidogrel package insert indicating a significant clinical link between specific CYP2C19 genetic variants and poor metabolism of clopidogrel. Of these variants, *2 and *3 are the most common and are associated with complete loss of enzyme activity. In patients who are carriers of a CYP2C19 *2 or *3 allele, the conversion of clopidogrel to its active metabolite may be reduced, which can lead to ischemic events and negative consequence for the patient. We examined the ability of the Verigene CLO assay (Nanosphere, Northbrook, IL) to identify CYP2C19 *2 and *3 polymorphisms in 1,286 unique whole blood samples. The Verigene CLO assay accurately identified homozygous and heterozygous *2 and *3 phenotypes with a specificity of 100% and a final call rate of 99.7%. The assay is fully automated and can produce a result in approximately 3.5 hours.
- Subjects
CLOPIDOGREL; ANTICOAGULANTS; CYTOCHROME P-450; METABOLITES; ENZYMES
- Publication
American Journal of Clinical Pathology, 2011, Vol 136, Issue 4, p604
- ISSN
0002-9173
- Publication type
journal article
- DOI
10.1309/AJCPCPU9Q2IRNYXC